SUPPLEMENTARY INFORMATION
FROM:
Overcoming Immune Tolerance Against Multiple Myeloma With Lentiviral Calnexin-engineered Dendritic Cells
Shuhong Han, Bei Wang, Matthew J Cotter, Li-Jun Yang, James Zucali, Jan S Moreb and Lung-Ji Chang
BACK TO ARTICLEDownload pluginsFigure S1. (tiff 109K)
Development of antigen-specific T cell response in vitro.
Figure S2. (tiff 105K)
Proportions of CD4+ and CD8+ cells in PBMCs of MM (multiple myeloma) patients (MM1 and MM2) and a healthy donor (HD).
Figure S3. (tiff 78K)
Calnexin (CNX) alone does not non-specifically upregulate effector cell functions, but supraphysiological expression of CNX in DCs promotes T cell response against known tumor antigens (HPV E6 and E7).
Figure S4. (tiff 199K)
Phenotype comparisons of DCs pulsed with cell lysates from different sources.
Figure S5. (tiff 229K)
Analyses of cytokine-producing CD4 and CD8 T cells stimulated by allogeneic mature DCs or monocytes.
